Javascript must be enabled to continue!
Outcome and survival in children with Non-Hodgkin’s lymphoma
View through CrossRef
Background Non-Hodgkin lymphoma is the third most common malignant tumor in children. It includes four major subtypes: Burkitt Lymphoma (BL), Lymphoblastic Lymphoma (LL), Diffuse Large B-cell Lymphoma (DLBL) and Anaplastic Large Cell Lymphoma (ALCL). The use of multidrug chemotherapy, radiation therapy, biologic agents, and improved diagnostic and supportive care resulted in better cure rates. Objective This study is to report prognosis and outcome of Non-Hodgkin lymphoma (NHL) patients at tertiary health care facility in King Faisal Specialist Hospital and Research Center, Jeddah (KFSHRC-J). Materials and Method A retrospective cross-sectional study of all eligible patients with Non-Hodgkin lymphoma (NHL), admitted, diagnosed and managed at King Faisal Specialist Hospital and Research Center, Jeddah from Jan 2005 to December 2016, previously untreated, with biopsy proven NHL and Age ≤ 15 years at diagnosis. Clinical data Research Form used to collect patient’s data from medical records. Demographic, Clinical and Survival data analysed using Statistical Package for Social Sciences. Results Thirty-one pediatric patients with biopsy proven Non-Hodgkin lymphoma (NHL) fulfilled the inclusion criteria. Twenty-six (80.6%) were males. Nineteen (61.3%) patients were ≤ 10 years of age at diagnosis, while 12 (38.7%) were>10 years of age. The mean age at diagnosis was 8.1years. The commonest primary site is abdomen (n=19, 61.3%), followed by Head & Neck (n=9, 28.1%), mediastinum (n=1, 3.1%), primary CNS (n=1, 3.1%), bone (n=1, 3.1%) and skin (n=1, 3.1%). Regarding histology 19 (61.3%) had Burkitt Lymphoma (BL), 6 (19.4%) had Diffuse Large B-cell Lymphoma (DLBL), 2(6.4%) had T-cell Lymphoblastic Lymphoma, 2 (6.4%) had T-cell rich B Cell Lymphoma, 1 (3.1%) had B-cell Lymphoma not otherwise specified and 1 (3.1%) had Cutaneous Anaplastic Large Cell Lymphoma (ALCL). Predominantly, patients presented in advanced stages III (n=18, 60%) and IV (n=10, 33%).Twenty-five (77.8%) patients completed treatment and are well to date while six of the patients (18.6%) died during the study period. Conclusion Children admitted to the (KFSHRC-J) appeared affected by non-Hodgkin Lymphoma at a younger age, with a higher incidence of Burkitt's Lymphoma. The predominant presenting site is abdomen followed by head/neck. They present mostly with advance disease. Survival rates are similar to those described in the literature of developed countries.
Title: Outcome and survival in children with Non-Hodgkin’s lymphoma
Description:
Background Non-Hodgkin lymphoma is the third most common malignant tumor in children.
It includes four major subtypes: Burkitt Lymphoma (BL), Lymphoblastic Lymphoma (LL), Diffuse Large B-cell Lymphoma (DLBL) and Anaplastic Large Cell Lymphoma (ALCL).
The use of multidrug chemotherapy, radiation therapy, biologic agents, and improved diagnostic and supportive care resulted in better cure rates.
Objective This study is to report prognosis and outcome of Non-Hodgkin lymphoma (NHL) patients at tertiary health care facility in King Faisal Specialist Hospital and Research Center, Jeddah (KFSHRC-J).
Materials and Method A retrospective cross-sectional study of all eligible patients with Non-Hodgkin lymphoma (NHL), admitted, diagnosed and managed at King Faisal Specialist Hospital and Research Center, Jeddah from Jan 2005 to December 2016, previously untreated, with biopsy proven NHL and Age ≤ 15 years at diagnosis.
Clinical data Research Form used to collect patient’s data from medical records.
Demographic, Clinical and Survival data analysed using Statistical Package for Social Sciences.
Results Thirty-one pediatric patients with biopsy proven Non-Hodgkin lymphoma (NHL) fulfilled the inclusion criteria.
Twenty-six (80.
6%) were males.
Nineteen (61.
3%) patients were ≤ 10 years of age at diagnosis, while 12 (38.
7%) were>10 years of age.
The mean age at diagnosis was 8.
1years.
The commonest primary site is abdomen (n=19, 61.
3%), followed by Head & Neck (n=9, 28.
1%), mediastinum (n=1, 3.
1%), primary CNS (n=1, 3.
1%), bone (n=1, 3.
1%) and skin (n=1, 3.
1%).
Regarding histology 19 (61.
3%) had Burkitt Lymphoma (BL), 6 (19.
4%) had Diffuse Large B-cell Lymphoma (DLBL), 2(6.
4%) had T-cell Lymphoblastic Lymphoma, 2 (6.
4%) had T-cell rich B Cell Lymphoma, 1 (3.
1%) had B-cell Lymphoma not otherwise specified and 1 (3.
1%) had Cutaneous Anaplastic Large Cell Lymphoma (ALCL).
Predominantly, patients presented in advanced stages III (n=18, 60%) and IV (n=10, 33%).
Twenty-five (77.
8%) patients completed treatment and are well to date while six of the patients (18.
6%) died during the study period.
Conclusion Children admitted to the (KFSHRC-J) appeared affected by non-Hodgkin Lymphoma at a younger age, with a higher incidence of Burkitt's Lymphoma.
The predominant presenting site is abdomen followed by head/neck.
They present mostly with advance disease.
Survival rates are similar to those described in the literature of developed countries.
Related Results
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Abstract
Introduction
Non-Hodgkin lymphoma (NHL) of the thyroid, a rare malignancy linked to autoimmune disorders, is poorly understood in terms of its pathogenesis and treatment o...
Liệu pháp điều trị trúng đích trong u lympho không Hodgkin
Liệu pháp điều trị trúng đích trong u lympho không Hodgkin
U lympho là bệnh lý ác tính dòng lympho thường gặp nhất trong huyết học, bao gồm u lympho Hodgkin và u lympho không Hodgkin. Trong đó, u lympho không Hodgkin chiếm đa số (80 - 85%)...
Endoscopic and Histopathological Characteristics of Gastrointestinal Lymphoma: A Multicentric Study
Endoscopic and Histopathological Characteristics of Gastrointestinal Lymphoma: A Multicentric Study
Background: Extranodal non-Hodgkin lymphoma (NHL) is more prevalent in the gastrointestinal (GI) tract than in other sites. This study aimed to determine the endoscopic characteris...
Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients
Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients
Introduction: Lymphoma is the most common underlying cause of secondary hemophagocytic lymphohistiocytosis (HLH). The detailed pathological subtypes of lymphomas presenting with HL...
Beneficios de la quimioterapia adyuvante en los resultados de supervivencia del cáncer de mama triple negativo pT1N0M0
Beneficios de la quimioterapia adyuvante en los resultados de supervivencia del cáncer de mama triple negativo pT1N0M0
Introduction Collaborative health research has proven to be an effective approach to addressing regional and international challenges in the diagnosis, treatment, and management o...
Non-invasive detection of lymphoma with circulating tumor DNA features and plasma protein marker.
Non-invasive detection of lymphoma with circulating tumor DNA features and plasma protein marker.
e19574 Background: Lymphoma is common cancer worldwide, a large group of lymphoid hematopoietic malignancies including Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) two maj...
Comparison of FDG-PET and Ga-67 Scintigraphy in the Evaluation of Lymphoma and Its Relationship to the Pathologic Diagnosis Using WHO Classification System.
Comparison of FDG-PET and Ga-67 Scintigraphy in the Evaluation of Lymphoma and Its Relationship to the Pathologic Diagnosis Using WHO Classification System.
Abstract
In the management of lymphoma patients, 18fluoro-2-deoxyglucose positron emission tomography (FDG-PET) has emerged as an important tool. However there are c...
CD5-Positive Marginal Zone Lymphoma: Clinicopathological Features And Survival Outcomes
CD5-Positive Marginal Zone Lymphoma: Clinicopathological Features And Survival Outcomes
Abstract
Background: CD5 expression in diffuse large B-cell lymphoma has a poor prognosis but the prognostic value of CD5 expression in marginal zone lymphoma is undefined....

